封面
市場調查報告書
商品編碼
1634193

全球神經外科市場 - 2025 - 2033

Global Neurosurgery Market - 2025 - 2033

出版日期: | 出版商: DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024年,全球神經外科市場規模達49.4億美元,預計2033年將達75.4億美元,2025-2033年預測期間複合年成長率為4.5%。

神經外科是一個專門的醫學領域,涉及神經系統問題的診斷、治療和復健。這包括大腦、脊髓、周邊神經和腦血管系統。神經外科醫師接受過培訓,可以進行各種外科手術來治療外傷、腫瘤、先天畸形和退化性疾病等疾病。該領域包括手術和非手術管理程序,允許採用更全面的患者護理方法,包括預防、診斷和復健。

神經外科作為一門活躍的專業,隨著技術和手術的突破而不斷變化。機器人輔助手術和術中影像等創新提高了手術精確度和病患治療效果。此外,對神經系統疾病的更好理解正在推動新治療方法的研究,這可能使神經外科醫生能夠治療更複雜的神經系統疾病。最終,神經外科是現代醫學的重要組成部分,因為它解決了世界各地人們所經歷的一些最困難的健康問題。

市場動態:

驅動程式和限制

技術進步

技術進步預計將成為全球神經外科市場成長的重要因素。隨著神經外科的發展,外科手術和設備的進步提高了各種神經系統疾病治療的精確度和療效。人工智慧 (AI) 和機器學習 (ML) 等現代技術的融合正在改變診斷和治療程序,從而為患者提供更準確的評估和個人化治療程序。

例如,2024 年3 月,中國科學院(CAS) 旗下香港研究中心推出了一款新的人工智慧(AI) 工具CARES Copilot 1.0,以協助複雜的腦部手術,即使醫療保健產業面臨複雜的腦部手術。 CARES Copilot 1.0人工智慧模型幫助神經外科醫生提供更有效率的臨床診斷,並在充分參考的基礎上做出更好的醫療判斷。

微創外科手術是神經外科領域的另一項重大成就。這些方法使用的切口比典型的開放性手術更小,可以減少患者創傷、加快恢復速度並減少併發症。神經內視鏡工具和機器人輔助手術系統等專用設備的引進,使得困難的手術能夠更準確、更有效率地進行。因此,患者可以受益於更快的恢復時間和更好的結果,從而增加了對這些革命性手術方法的需求。

此外,神經外科市場正在經歷研發的增加,重點是開發可提高手術能力的下一代設備。製造商正在逐步投資開發新的電動工具,這些工具結合了即時成像和人工智慧功能,為外科醫生在手術過程中提供了無與倫比的精確度。這種對技術創新的重視不僅提高了營運效率,而且符合客製化醫療日益成長的趨勢,即根據患者獨特的醫療狀況,根據患者的個人需求量身定做治療方案。

例如,2024 年 4 月,Insightec 宣佈在歐洲推出其下一代神經外科平台。 Exablate Prime 也獲得了 CE 許可。這款革命性的設備極大地增強了現有的 Exablate Neuro 平台,該平台使用磁振造影 (MRI) 引導的聚焦超音波技術。 Exablate Prime 旨在治療特發性震顫和帕金森氏症等藥物難治性運動障礙,允許將無切口神經外科手術作為門診手術,為患者提供一種非侵入性治療替代方案,最大限度地縮短康復時間和住院時間。

神經外科設備成本高

神經外科設備的高成本等因素預計將阻礙全球神經外科市場。神經外科設備的高成本預計將嚴重阻礙全球神經外科產業的成長。隨著對改進手術技術的需求不斷成長,複雜設備的成本也不斷增加。對於許多醫療機構來說,購買和維護先進技術的成本可能是一個重大挑戰,特別是在經濟有限的地區。由於持續需要投資指導員工有效地使用這些新儀器,這種情況變得更加複雜,這又增加了醫院預算的成本。

例如,根據美國國立衛生研究院的數據,深部腦部刺激裝置的成本從 10,000 美元到 14,000 美元不等。深部腦部刺激的手術和設備總成本(每位患者)從 27,497 美元到 35,531 美元不等。

目錄

第 1 章:方法與範圍

第 2 章:定義與概述

第 3 章:執行摘要

第 4 章:動力學

  • 影響因素
    • 促進要素
    • 技術進步
    • 限制
    • 神經外科設備成本高昂
    • 機會
    • 影響分析

第 5 章:產業分析

  • 波特五力分析
  • 供應鏈分析
  • 定價分析
  • 監管分析
  • 報銷分析
  • 專利分析
  • SWOT分析
  • DMI 意見

第 6 章:依產品

  • 神經介入器材
  • 神經外科軟體
  • 神經內視鏡
  • 放射外科系統
  • 神經外科消融設備
  • 其他

第 7 章:按申請

  • 腦腫瘤
  • 腦血管外科
  • 皮質映射
  • 帕金森氏症和震顫
  • 其他

第 8 章:依年齡層

  • 兒科
  • 成人
  • 老年科

第 9 章:最終用戶

  • 醫院
  • 神經外科中心
  • 其他

第 10 章:按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲

第 11 章:競爭格局

  • 競爭場景
  • 市場定位/佔有率分析
  • 併購分析

第 12 章:公司簡介

  • Medtronic
    • 公司概況
    • 產品組合和描述
    • 財務概覽
    • 主要進展
  • Abbott
  • Boston Scientific Corporation
  • Elekta
  • Brainlab AG
  • B. Braun SE
  • MicroVention, Inc.
  • Aleva Neurotherapeutics
  • Integra LifeSciences
  • Stryker

第 13 章:附錄

簡介目錄
Product Code: MD9006

The global neurosurgery market reached US$ 4.94 billion in 2024 and is expected to reach US$ 7.54 billion by 2033, growing at a CAGR of 4.5% during the forecast period 2025-2033.

Neurosurgery is a specialized field of medicine concerned with the diagnosis, treatment, and rehabilitation of neurological concerns. This encompasses the brain, spinal cord, peripheral nerves, and cerebrovascular system. Neurosurgeons are trained to undertake a wide range of surgical procedures to treat disorders such as traumatic injuries, tumors, congenital abnormalities, and degenerative diseases. The field comprises both operative and non-operative management procedures, allowing for a more comprehensive approach to patient care, including prevention, diagnosis, and rehabilitation.

Neurosurgery, as an active specialization, constantly changes in response to technological and surgical breakthroughs. Innovations like robotic-assisted surgery and intraoperative imaging improve procedure precision and patient outcomes. Furthermore, a better understanding of neurological diseases is driving research into new treatment methods, which may allow neurosurgeons to manage more complex neurological conditions. Ultimately, neurosurgery is an important part of modern medicine since it addresses some of the most difficult health concerns that people experience around the world.

Market Dynamics: Drivers & Restraints

Technological advancements

The Technological Advancements are expected to be a significant factor in the growth of the global neurosurgery market. As neurosurgery evolves, advances in surgical procedures and equipment improve the precision and efficacy of treatments for a variety of neurological diseases. The integration of modern technology such as artificial intelligence (AI) and machine learning (ML) is transforming diagnostic and therapeutic procedures, allowing for more accurate assessments and personalized treatment procedures for patients.

For instance, in March 2024, A Hong Kong-based research center under the Chinese Academy of Sciences (CAS) launched a new artificial intelligence (AI) tool CARES Copilot 1.0 to assist in complex brain surgery, even as the healthcare industry deals with an inadequate number of specialized databases for this procedure. CARES Copilot 1.0 AI model to help neurosurgeons provide more efficient clinical diagnoses and make better medical judgments based on sufficient references.

Minimally invasive surgical procedures are an additional significant accomplishment in neurosurgery. These approaches, which use smaller incisions than typical open surgeries, result in less patient trauma, faster recovery, and fewer complications. The introduction of specialized devices, such as neuroendoscopic tools and robotic-assisted surgical systems, has enabled difficult procedures to be performed more accurately and efficiently. As a result, patients benefit from faster recovery times and better outcomes, increasing demand for these revolutionary surgical approaches.

Furthermore, the neurosurgery market is experiencing a rise in R&D focused on developing next-generation equipment that improves surgical capabilities. Manufacturers are progressively investing in the development of new power tools that incorporate real-time imaging and AI capabilities, giving surgeons unparalleled levels of precision during procedures. This emphasis on technology innovation not only enhances operational efficiency but also corresponds with the growing trend toward customized medicine, in which therapies are tailored to the individual needs of patients based on their distinct medical profiles.

For instance, in April 2024, Insightec announced the launch of its next-generation neurosurgical platform in Europe. Exablate Prime also received CE clearance. This revolutionary device substantially enhances the existing Exablate Neuro platform, which uses magnetic resonance imaging (MRI)-guided focused ultrasound technology. Exablate Prime, designed to treat medication-refractory movement disorders such as essential tremor and Parkinson's disease, allows for incision-less neurosurgery as an outpatient operation, allowing patients a non-invasive treatment alternative that minimizes recovery time and hospital stays.

High costs of neurosurgery equipment

Factors such as high costs of neurosurgery equipment are expected to hamper the global neurosurgery market. The high costs of neurosurgical devices are expected to severely impede the growth of the global neurosurgery industry. As the need for improved surgical technology grows, so does the cost of the complex equipment. The cost of buying and maintaining advanced technology can be a significant challenge for many healthcare facilities, especially in areas with limited economies. This scenario is further complicated by the ongoing need to invest in instructing staff to utilize these new instruments efficiently, which adds another layer of cost to hospitals' budgets.

For instance, according to the National Institute of Health, the cost of a deep brain stimulation device ranges from $10,000 to $14,000. The total operative and device costs (per patient) range from $27,497 to $35,531 for deep brain stimulation.

Segment Analysis

The global neurosurgery market is segmented based on product, application, age group, end-user, and region.

Neuro interventional devices segment is expected to dominate the global neurosurgery market share

The radiofrequency coils segment is anticipated to dominate the global neurosurgery market owing to its technological advancements, recent launches and approvals, and increase in the number of neurological disorders. One of the primary benefits of neuro-interventional devices is their capacity to facilitate minimally invasive operations, which are associated with shorter recovery times, fewer postoperative problems, and less trauma for patients when compared to traditional open surgeries. These devices comprise several instruments including stents, embolic coils, and neurothrombectomy devices, all of which are intended to treat problems such as aneurysms and ischemic strokes using endovascular techniques. As healthcare practitioners become more aware of the benefits of these procedures, the demand for neuro-interventional devices is projected to increase significantly.

Furthermore, technological improvements have resulted in the creation of increasingly complex neuro-interventional devices that improve procedural accuracy and safety. Neurosurgeons may now execute difficult operations with better precision because of developments in robotics and imaging technology. This technical advancement not only improves surgical outcomes but also broadens the types of conditions that can be treated with these devices. As a result, healthcare institutions are more likely to invest in neuro-interventional technology, strengthening their position as an important segment of the neurosurgery market.

For instance, in February 2024, Royal Philips launched the new Azurion neuro biplane interventional system, which significantly improves its image-guided therapeutic system. The technology is intended to streamline neurovascular operations, allowing care teams to make faster judgments, treat more patients, and achieve better results. It has superior 2D and 3D imaging capabilities, as well as adjustable X-ray detector positioning. The device allows neuro-interventionists to carry out procedures more efficiently, perhaps increasing patient outcomes. This improves the experience for both staff and patients while also helping to reduce the cost of care. The Azurion neuro biplane system incorporates Philips' ClarityIQ low-dose imaging technology, neuro-specific tools, and services, resulting in a fully integrated solution for smooth procedural workflows, precise diagnosis, and treatment.

Moreover, in June 2024, MicroVention, a subsidiary of Terumo Corporation, launched its LVIS EVO Intraluminal Support Device in the United States. It is specifically intended for the treatment of wide-neck intracranial aneurysms. This novel device is now commercially accessible and represents a substantial improvement in neurovascular therapies.

Geographical Analysis

North America is expected to hold a significant position in the global neurosurgery market share

North America will likely account for a significant share of the global neurosurgery market, owing to its advanced healthcare infrastructure, a high prevalence of neurological disorders, technological advancements, and recent launches and approvals. One of the key drivers of the North America neurosurgery market is a strong healthcare system that allows for better surgical methods and technology. The United States, in particular, has established itself as a leader in medical technology development, with a number of major companies functioning in the neurosurgical field. These corporations constantly invest in R&D to develop new devices and improve existing ones. The existence of large manufacturers, as well as a robust regulatory environment, make it easier to introduce advanced neurosurgical devices, which enhances patient care.

For instance, in March 2024, Silk Road Medical, Inc., a company focused on reducing the risk of stroke and its devastating impact, announced that it had launched its Tapered ENROUTE Transcarotid Stent System to hospitals in the United States. This launch expands upon the company's prior ENROUTE Transcarotid Stent System, offering additional configurations to better tailor the Transcarotid Artery Revascularization (TCAR) procedure to patient anatomy.

Moreover, in April 2024, Expanse ICE announced that the ICE Aspiration System had received 510(k) clearance from the U.S. Food and Drug Administration. The ICE System is specifically designed to address the complex challenges associated with peripheral thrombectomies. Blood clots are the third most common vascular disease.

Asia Pacific is growing at the fastest pace in the global neurosurgery market

The Asia Pacific region is emerging as the fastest-growing market for neurosurgery, owing to a combination of demographic trends, increased healthcare investment, recent launches, and a rising number of neurological disorders. One of the most significant technical advances in the APAC neurosurgery market is the incorporation of robotics and minimally invasive techniques. These innovations enable more accurate surgical procedures, lowering the trauma associated with traditional open surgeries. Additionally, high-definition imaging tools have transformed preoperative planning and intraoperative guidance in neurosurgery. Advanced imaging modalities, such as MRI and CT scans, provide extensive information about brain anatomy, allowing surgeons to see complicated structures before and during surgery. This ability improves surgical precision, lowers the risk of complications, and, eventually, leads to improved patient results. Furthermore, the introduction of artificial intelligence (AI) and machine learning into diagnostic and surgical technologies improves the efficiency and effectiveness of neurosurgical treatments.

For instance, in February 2024, Indian medical imaging AI company InMed AI launched a new AI-powered tool for screening traumatic brain injuries (TBI). The Neuroshield CT TBI is a decision support tool for detecting and quantifying intracranial hemorrhage, fracture, and midline shift. Utilizing AI, it automatically processes brain CT images and alerts clinicians of critical findings.

Competitive Landscape

The major global players in the global neurosurgery market include Medtronic, Abbott, Boston Scientific Corporation, Elekta, Brainlab AG, B. Braun SE, MicroVention, Inc., Aleva Neurotherapeutics, Integra LifeSciences, and Stryker among others.

Emerging Players

Neurotech Innovations, Cadence Neuroscience, and Synaptive Medical among others

Key Developments

  • In September 2024, ZEISS Medical Technology launched the KINEVO 900 S. The latest Robotic Visualization System is a further development of the successful ZEISS KINEVO 900 platform. With the best digital visualization, collaborative assistant functions, and connected intelligence, ZEISS KINEVO 900 S offers more clarity for complex surgical procedures in neurosurgery and other surgical disciplines.
  • In November 2023, Amrita Hospital, Kochi opened Kerala's first neuro endoscopy center, the Amrita Centre for Neuro Endoscopy (ACNE). The center has an expert team in skull base, cranial, spine, robotic, and pediatric endoscopy, providing specialized care in endoscopic neurosurgery.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global neurosurgery market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product
  • 3.2. Snippet by Application
  • 3.3. Snippet by Age Group
  • 3.4. Snippet by End-User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
    • 4.1.2. Technological Advancements
    • 4.1.3. Restraints
    • 4.1.4. High Costs of Neurosurgery Equipment
    • 4.1.5. Opportunity
    • 4.1.6. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Patent Analysis
  • 5.7. SWOT Analysis
  • 5.8. DMI Opinion

6. By Product

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 6.1.2. Market Attractiveness Index, By Product
  • 6.2. Neuro Interventional Devices*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Neurosurgery Software
  • 6.4. Neuroendoscopes
  • 6.5. Radiosurgery Systems
  • 6.6. Neurosurgical Ablation Devices
  • 6.7. Others

7. By Application

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 7.1.2. Market Attractiveness Index, By Application
  • 7.2. Brain Tumors*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Cerebrovascular Surgery
  • 7.4. Cortical Mapping
  • 7.5. Parkinson's Disease and Tremors
  • 7.6. Others

8. By Age Group

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age group
    • 8.1.2. Market Attractiveness Index, By Age group
  • 8.2. Pediatric
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Adult
  • 8.4. Geriatric

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Neurosurgery Centers
  • 9.4. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.7.1. U.S.
      • 10.2.7.2. Canada
      • 10.2.7.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.7.1. Germany
      • 10.3.7.2. U.K.
      • 10.3.7.3. France
      • 10.3.7.4. Spain
      • 10.3.7.5. Italy
      • 10.3.7.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.7.1. Brazil
      • 10.4.7.2. Argentina
      • 10.4.7.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.7.1. China
      • 10.5.7.2. India
      • 10.5.7.3. Japan
      • 10.5.7.4. South Korea
      • 10.5.7.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Medtronic*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Abbott
  • 12.3. Boston Scientific Corporation
  • 12.4. Elekta
  • 12.5. Brainlab AG
  • 12.6. B. Braun SE
  • 12.7. MicroVention, Inc.
  • 12.8. Aleva Neurotherapeutics
  • 12.9. Integra LifeSciences
  • 12.10. Stryker

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us